Polymorphism Studies
Polymorphism Studies

Polymorphism Studies
Polymorphism Studies
Polymorphism: From Material Science to a Pillar of Pharmaceutical Development
Polymorphism was once a topic reserved for materials scientists—but that changed dramatically in 1998 with the high-profile case of Ritonavir, where a sudden polymorphic transformation caused the drug to fail dissolution tests, leading to a product recall. Since then, polymorphism has become a cornerstone of pharmaceutical development, triggering countless studies across the industry.
At the forefront of this transformation is our expert, Dr. Ravikiran, a true pioneer in pharmaceutical polymorphism. With over 50,000 PXRD scans analyzed, numerous publications, and a role as a reviewer for leading pharmaceutical journals, he has solved some of the industry’s most complex solid-state challenges. As an innovator of novel solid forms, his deep expertise helps pharmaceutical teams navigate the fine line between compliance, performance, and innovation.
Alcoax: Your Complete Partner in Polymorphism Studies
We offer end-to-end polymorphism solutions tailored to meet both regulatory and patent requirements:
Whether you’re facing a regulatory challenge or looking to future-proof your formulation, Alcoax delivers science-backed, regulator-ready solutions for all your polymorphism study needs.